4,392 Shares in Novartis AG $NVS Bought by Financial & Tax Architects LLC

Financial & Tax Architects LLC bought a new position in Novartis AG (NYSE:NVS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 4,392 shares of the company’s stock, valued at approximately $626,000.

Other large investors have also added to or reduced their stakes in the company. Turtle Creek Wealth Advisors LLC bought a new position in shares of Novartis during the 3rd quarter valued at $430,000. KG Capital Management boosted its stake in shares of Novartis by 11.9% in the 3rd quarter. KG Capital Management now owns 2,289 shares of the company’s stock worth $326,000 after buying an additional 243 shares during the last quarter. Mather Group LLC. grew its holdings in shares of Novartis by 1.4% in the third quarter. Mather Group LLC. now owns 9,708 shares of the company’s stock worth $1,384,000 after acquiring an additional 138 shares during the period. Hudock Inc. grew its holdings in shares of Novartis by 12.1% in the third quarter. Hudock Inc. now owns 2,410 shares of the company’s stock worth $344,000 after acquiring an additional 261 shares during the period. Finally, Triumph Capital Management grew its holdings in shares of Novartis by 9.8% in the third quarter. Triumph Capital Management now owns 826 shares of the company’s stock worth $118,000 after acquiring an additional 74 shares during the period. Institutional investors own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Citigroup reiterated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Bank of America restated a “buy” rating on shares of Novartis in a research note on Tuesday, September 8th. HSBC upgraded Novartis from a “reduce” rating to a “hold” rating and boosted their price target for the company from $123.00 to $136.00 in a research note on Thursday, September 10th. Finally, Royal Bank Of Canada initiated coverage on shares of Novartis in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Six equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $145.60.

Novartis Stock Up 2.4%

NVS opened at $150.34 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. Novartis AG has a 1-year low of $121.57 and a 1-year high of $170.46. The company has a market capitalization of $286.86 billion, a PE ratio of 16.92, a PEG ratio of 2.66 and a beta of 0.41. The firm’s 50 day simple moving average is $148.46 and its two-hundred day simple moving average is $150.47.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. As a group, equities analysts forecast that Novartis AG will post 8.91 EPS for the current year.

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.